生脉注射液和丹参注射液联合治疗肺癌晚期合并冠心病的临床效果

Clinical effect of Shengmai injection combined with Danshen injection in the treatment of advanced lung cancer with coronary heart disease

目的分析生脉注射液和丹参注射液联合治疗肺癌晚期合并冠心病的临床效果。方法回顾性分析本院2016年5月至2018年3月收治的84例肺癌晚期合并冠心病患者的临床资料,按照治疗方法的不同将其分为对照组(42例,常规西医治疗)和观察组(42例,生脉注射液和丹参注射液联合治疗)。比较两组患者临床疗效、不良反应发生情况及治疗前、后生活质量。结果观察组的治疗总有效率显著高于对照组,差异具有统计学意义(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。治疗后,两组生理机能、生理职能、躯体疼痛、一般健康状况、精力、社会功能、情感职能及精神健康评分均升高,且观察组高于对照组,差异具有统计学意义(P<0.05)。结论生脉注射液和丹参注射液联合治疗肺癌晚期合并冠心病可改善患者临床症状、提高其生活质量,且安全性高,不良反应少,值得临床应用推广。

Objective To analyze the clinical effect of Shengmai injection combined with Danshen injection in the treatment of advanced lung cancer with coronary heart disease.Methods The clinical data of 84 patients with advanced lung cancer and coronary heart disease admitted in our hospital from May 2016 to March 2018 were retrospectively analyzed.They were divided into control group (42 cases,routine western medicine treatment) and observation group (42 cases,Shengmai injection and Danshen injection combined treatment) according to different treatment methods.The clinical efficacy,adverse reactions and quality of life before and after treatment were compared between the two groups.Results The total effective rate of treatment in the observation group was significantly higher than that of the control group,the difference was statistically significant (P<0.05).There was no significant difference in the total incidences of adverse reactions between the two groups (P>0.05).After treatment,the SF-36 scores of physiological function,physiological function,physical pain,general health condition,energy,social function,emotional function and mental health in both groups increased,and those in the observation group were higher than the control group,the differences were statistically significant (P<0.05).Conclusion The combination of Shengmai injection and Danshen injection in the treatment of advanced lung cancer with coronary heart disease can improve the clinical symptoms and quality of life of patients,with high safety and less adverse reactions,which is worthy of clinical application and promotion.